Latest Period
Q4 2025
Security Snapshot
Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH) Institutional Ownership
CUSIP: 252828108
13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026
Institutions Reporting
167
Shares (Excl. Options)
49,121,649
Price
$41.21
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- DNTH on Nasdaq
- Shares outstanding
- 51,647,137
- Price per share
- $91.66
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 49,121,649
- Total reported value
- $2,024,311,315
- % of total 13F portfolios
- 0.01%
- Share change
- +1,507,383
- Value change
- +$67,678,158
- Number of holders
- 167
- Price from insider filings
- $91.66
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock is tracked under CUSIP 252828108.
- 167 institutions reported positions in Q4 2025.
- 12 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 167 to 67 between Q4 2025 and Q1 2026.
- Reported value moved from $2,024,311,315 to $497,534,753.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 167 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 252828108?
CUSIP 252828108 identifies DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 252828108:
Significant Owners of Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +7.1% | $234,944,605 | +$58,553,941 | 5,970,638 | +33% | FMR LLC | 30 Sep 2025 |
| Point72 Asset Management, L.P. | 6.9% | +32% | $107,936,599 | +$31,151,331 | 2,981,674 | +41% | Point72 Asset Management, L.P. | 31 Dec 2025 |
| BlackRock, Inc. | 5.1% | +2% | $221,045,616 | +$86,760,776 | 2,634,004 | +65% | BlackRock, Inc. | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 6% | -35% | $94,544,735 | -$45,431,000 | 2,611,733 | -32% | RA Capital Management, L.P. | 31 Dec 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.5% | $101,431,000 | 2,577,662 | Wellington Management Group LLP | 30 Sep 2025 | |||
| Octagon Capital Advisors LP | 6.1% | -14% | $95,095,846 | +$12,060,775 | 2,416,667 | +15% | Octagon Capital Advisors LP | 30 Sep 2025 |
| Fairmount Funds Management LLC | 4.9% | -50% | $72,191,285 | -$64,524,950 | 2,139,635 | -47% | Fairmount Funds Management LLC | 21 Nov 2025 |
| Avidity Partners Management LP | 4.9% | -50% | $70,995,168 | -$43,010,234 | 2,104,184 | -38% | Avidity Partners Management LP | 17 Nov 2025 |
| TCG Crossover GP II, LLC | 4.7% | $32,660,322 | 1,501,624 | TCG Crossover GP II, LLC | 31 Mar 2025 | |||
| BCLS Fund III Investments, LP | 3.1% | -55% | $51,780,350 | -$45,896,187 | 1,315,892 | -47% | BCLS Fund III Investments, LP | 30 Sep 2025 |
| Vestal Point Capital, LP | 3% | -70% | $46,433,000 | -$79,487,000 | 1,180,000 | -63% | Vestal Point Capital, LP | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 3.1% | $20,060,000 | 1,000,000 | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2025 |
As of 31 Dec 2025, 167 institutional investors reported holding 49,121,649 shares of Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH). This represents 95% of the company’s total 51,647,137 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH) together control 72% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 12% | 6,431,329 | +7.7% | 0.01% | $265,035,068 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.8% | 2,503,190 | -2.9% | 0.02% | $103,156,459 |
| Octagon Capital Advisors LP | 4.7% | 2,416,667 | 0% | 12% | $99,590,847 |
| Fairmount Funds Management LLC | 4.1% | 2,137,191 | -35% | 6.7% | $88,073,641 |
| Avidity Partners Management LP | 4.1% | 2,104,184 | -34% | 25% | $86,713,423 |
| VANGUARD GROUP INC | 4% | 2,048,452 | +25% | 0% | $84,416,707 |
| BlackRock, Inc. | 3.7% | 1,915,236 | +43% | 0% | $78,926,876 |
| TCG Crossover Management, LLC | 3.2% | 1,676,624 | 0% | 2.3% | $69,093,675 |
| RA CAPITAL MANAGEMENT, L.P. | 3.1% | 1,611,733 | -44% | 0.68% | $66,419,517 |
| STATE STREET CORP | 2.9% | 1,507,619 | +125% | 0% | $62,128,979 |
| BRAIDWELL LP | 2.5% | 1,273,935 | +53% | 1.7% | $52,498,861 |
| Point72 Asset Management, L.P. | 2.3% | 1,166,088 | -43% | 0.08% | $48,054,486 |
| CITADEL ADVISORS LLC | 2.1% | 1,068,934 | +5.5% | 0.03% | $44,050,770 |
| MARSHALL WACE, LLP | 2% | 1,008,533 | +76% | 0.04% | $41,561,643 |
| Polar Capital Holdings Plc | 1.9% | 1,004,728 | +34% | 0.19% | $41,404,841 |
| VR ADVISER, LLC | 1.9% | 1,000,000 | +4.1% | 2% | $41,210,000 |
| ALLIANCEBERNSTEIN L.P. | 1.6% | 834,383 | -2.1% | 0.01% | $34,384,923 |
| BAKER BROS. ADVISORS LP | 1.5% | 789,759 | 0% | 0.19% | $32,545,968 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.5% | 750,136 | +11% | 4.5% | $30,913,105 |
| Bain Capital Life Sciences Investors, LLC | 1.4% | 743,592 | -43% | 2.3% | $30,643,426 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 676,658 | +26% | 0% | $27,890,189 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | 667,216 | +356% | 0.02% | $27,495,971 |
| Catalio Capital Management, LP | 1.3% | 653,572 | -2.1% | 5% | $26,933,702 |
| Tri Locum Partners LP | 1.2% | 622,403 | +240% | 3.3% | $25,649,228 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.2% | 616,033 | +185% | 0% | $25,388,000 |
Institutional Holders of Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 5,928,849 | $497,534,753 | +$121,166,742 | $83.92 | 67 |
| 2025 Q4 | 49,121,649 | $2,024,311,315 | +$67,678,158 | $41.21 | 167 |
| 2025 Q3 | 46,828,772 | $1,842,663,442 | +$358,133,968 | $39.35 | 140 |
| 2025 Q2 | 39,106,709 | $728,558,630 | +$24,440,177 | $18.63 | 101 |
| 2025 Q1 | 37,715,319 | $685,461,303 | +$43,246,773 | $18.14 | 97 |
| 2024 Q4 | 35,126,689 | $765,706,199 | +$63,092,353 | $21.80 | 94 |
| 2024 Q3 | 31,364,805 | $858,714,506 | +$44,837,092 | $27.38 | 90 |
| 2024 Q2 | 29,702,499 | $768,778,734 | +$87,583,327 | $25.88 | 74 |
| 2024 Q1 | 26,075,021 | $782,250,559 | +$479,966,613 | $30.00 | 75 |
| 2023 Q4 | 10,291,119 | $106,507,945 | +$518,588 | $10.40 | 38 |
| 2023 Q3 | 10,072,640 | $136,328,208 | +$136,328,208 | $13.67 | 30 |